Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
Supportive Care in Cancer, 09/23/09

Hesketh PJ et al. – This analysis confirmed the relevance of several previously reported risk factors for CINV in patients receiving chemotherapy. Aprepitant improved complete response regardless of risk and eliminated the increased risk of CINV associated with the female gender.

Methods

Patients from two double-blind, placebo-controlled trials were randomized to an active-control group
Primary endpoint was complete response (no emesis or rescue therapy use)
Multivariate logistic regression models used to assess impact of treatment with aprepitant and previously reported risk factors
Modified intent-to-treat approach

Results

Treatment with aprepitant , male gender , cisplatin dose <80 mg/m2 , age ?65 years (p?=?0.021), and five or more alcoholic drinks per week were all significantly associated with improved complete response
Aprepitant improved complete response regardless of risk for all factors and neutralized the risk associated with female gender

<< Previous
Long-term survival in chronic myelocytic leukemia after a first...

Next >>
Interstitial fluid pressure as a prognostic factor in cervical...